🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

2 recruiting trials

for Relapsed or Refractory IDH1 Mutation-Positive Acute Myeloid Leukemia

A Clinical Trial of Olutasidenib in Patients With Acute Myeloid Leukemia NCT07604064Phase 21 site📍 Tokyo and Other Japanese Cities Kissei Pharmaceutical Co., Ltd. · Tests: Olutasidenib Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation NCT02074839Phase 130 sites📍 Birmingham📍 Phoenix📍 Duarte Institut de Recherches Internationales Servier · Tests: AG-120
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy